Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01316939
Registration number
NCT01316939
Ethics application status
Date submitted
3/03/2011
Date registered
16/03/2011
Date last updated
7/09/2017
Titles & IDs
Public title
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Query!
Scientific title
A 52 Week Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Query!
Secondary ID [1]
0
0
2010-022383-12
Query!
Secondary ID [2]
0
0
114157
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
SHIELD-2
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Crohn's Disease
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Inflammatory bowel disease
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Crohn's disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - GSK1605786A
Treatment: Drugs - Placebo
Treatment: Drugs - GSK1605786A
Placebo Comparator: Placebo - Placebo
Experimental: GSK1605786A once daily - 500 milligrams once daily
Experimental: GSK1605786A twice daily - 500 milligrams twice daily
Treatment: Drugs: GSK1605786A
GSK1605786A 500 milligrams once daily
Treatment: Drugs: Placebo
Placebo
Treatment: Drugs: GSK1605786A
GSK1605786A 500 milligrams twice daily
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants in Clinical Remission (Crohn's Disease Activity Index , CDAI Score <150 Points) at Both Weeks 28 and 52 of the 52-week Treatment Period
Query!
Assessment method [1]
0
0
Clinical remission is defined as a CDAI score <150 points. In the missing=no effect imputation, participants with missing CDAI scores was considered not to be in clinical remission. Data for percentage of participants in at both Weeks 28 and 52 of the 52-week treatment period have been presented.
Query!
Timepoint [1]
0
0
Week 28 and 52
Query!
Secondary outcome [1]
0
0
Percentage of Participants in Clinical Remission (CDAI Score <150 Points) and Not Taking Corticosteroids at Both Weeks 28 and 52 of the 52-week Treatment Period
Query!
Assessment method [1]
0
0
Clinical remission is defined as a CDAI score <150 points. A participant was considered to be not taking corticosteroids at Weeks 28 and 52 if the participant had not taken a corticosteroid for the 8 days prior to and the day of the CDAI assessment for each of Weeks 28 and 52. In the missing=no effect imputation, participants with missing CDAI scores was considered not to be in clinical remission. Data for percentage of participants in clinical remission and not taking corticosteroids at both Weeks 28 and 52 of the 52-week treatment period have been presented.
Query!
Timepoint [1]
0
0
Week 28 and 52
Query!
Secondary outcome [2]
0
0
Percentage of Participants in Clinical Remission at Both Weeks 28 and 52 of the 52-week Treatment Period Among Those Participants Who Were in Clinical Remission at Baseline
Query!
Assessment method [2]
0
0
Clinical remission is defined as a CDAI score <150 points. Among participants in remission at baseline, the percentage of participants with clinical remission at both Weeks 28 and 52 of the treatment period using the no effect imputation for missing data were to be compared between each GSK1605786A dose group and placebo using Fisher's exact test. Participants with missing CDAI scores were to be considered not to be in remission according to the missing=no effect imputation. The limited data resulting from early termination of Study CCX114157 did not allow any conclusions to be drawn about the efficacy of GSK1605786A in the maintenance of clinical remission in participants with Crohn's disease.
Query!
Timepoint [2]
0
0
Week 28 and 52
Query!
Secondary outcome [3]
0
0
Percentage of Participants in Clinical Remission at All Visits (Continuous Clinical Remission) During the 52-week Treatment Period Among Participants in Clinical Remission at Baseline
Query!
Assessment method [3]
0
0
The percentage of participants with clinical remission at all visits during the 52-week treatment period were to be summarized by treatment group for the subset of participants in remission at baseline, using the no effect imputation for missing data. Participants with missing CDAI scores were to be considered not to be in remission according to the missing=no effect imputation. Comparisons between each GSK1605786A dose group and placebo were to be made using Fisher's exact test.The limited data resulting from early termination of Study CCX114157 did not allow any conclusions to be drawn about the efficacy of GSK1605786A in the maintenance of clinical remission in participants with Crohn's disease.
Query!
Timepoint [3]
0
0
Upto Week 52
Query!
Secondary outcome [4]
0
0
Percentage of Participants in Clinical Remission at Week 52
Query!
Assessment method [4]
0
0
The limited data resulting from early termination of Study CCX114157 did not allow any conclusions to be drawn about the efficacy of GSK1605786A in the maintenance of clinical remission in participants with Crohn's disease.
Query!
Timepoint [4]
0
0
Week 52
Query!
Secondary outcome [5]
0
0
Percentage of Participants With a Clinical Response (CDAI Decrease >=100 Points) at Both Weeks 28 and 52 of the 52-week Treatment Period
Query!
Assessment method [5]
0
0
Clinical response is defined as a reduction from the induction study baseline CDAI score of >=100 points. The percentage of participants with a clinical response at both Weeks 28 and 52 of the 52-week maintenance treatment period in the ITT population using the no effect imputation for missing data were to be compared between each GSK1605786A dose group and placebo using Fisher's exact test. Participants with missing CDAI scores were to be considered non-responders according to the missing=no effect imputation. The limited data resulting from early termination of Study CCX114157 did not allow any conclusions to be drawn about the efficacy of GSK1605786A in the maintenance of clinical remission in participants with Crohn's disease.
Query!
Timepoint [5]
0
0
Week 28 and 52
Query!
Secondary outcome [6]
0
0
Time to Induction of Clinical Remission in Participants Who Had Achieved Clinical Response During Induction Therapy But Were Not in Clinical Remission at Baseline
Query!
Assessment method [6]
0
0
The duration of time participants maintained clinical remission during the 52-week treatment period was to be defined as the time between Week 0 and the first visit where remission was not observed in those participants in remission at baseline. These time periods were to be summarized by treatment group using quartiles and their corresponding confidence intervals. Comparisons between each GSK1605786A dose group and placebo were to be made using log-rank tests. The limited data resulting from early termination of Study CCX114157 did not allow any conclusions to be drawn about the efficacy of GSK1605786A in the maintenance of clinical remission in participants with Crohn's disease.
Query!
Timepoint [6]
0
0
Upto Week 52
Query!
Secondary outcome [7]
0
0
Change From Baseline in CDAI Score at Weeks 4, 8, 12, 20, 28, 36, 44, and 52
Query!
Assessment method [7]
0
0
The CDAI score is used to quantify the symptoms of participants with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity. CDAI scores and changes in CDAI scores during the 52-week treatment period were to be summarized by treatment group at Weeks 4, 8, 12, 20, 28, 36, 44, and 52. The limited data resulting from early termination of Study CCX114157 did not allow any conclusions to be drawn about the efficacy of GSK1605786A in the maintenance of clinical remission in participants with Crohn's disease. Baseline was defined as value at Week 0. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at the time of assessment.
Query!
Timepoint [7]
0
0
Baseline (Week 0) and Weeks 4, 8, 12, 20, 28, 36, 44, and 52
Query!
Secondary outcome [8]
0
0
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 52
Query!
Assessment method [8]
0
0
The IBDQ consists of a self-administered 32-item questionnaire that evaluates quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. The IBDQ questionnaire was to be completed by each participant at baseline and at Weeks 28, and 52. The response to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score can range between 32 to 224 with higher scores indicating a better quality of life. The limited data resulting from early termination of Study CCX114157 did not allow any conclusions to be drawn about the efficacy of GSK1605786A in the maintenance of clinical remission in participants with Crohn's disease. Baseline was defined as value at Week 0. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at the time of assessment.
Query!
Timepoint [8]
0
0
Baseline (Week 0) and Week 52
Query!
Secondary outcome [9]
0
0
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [9]
0
0
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed in the definition above, or is an event of possible drug-induced liver injury.
Query!
Timepoint [9]
0
0
Upto 56 weeks
Query!
Secondary outcome [10]
0
0
Change From Baseline in Vital Sign Systolic Blood Pressure Systolic (SBP) and Diastolic Blood Pressure (DBP) Upto Week 56
Query!
Assessment method [10]
0
0
Vital sign assessments included SBP and DBP collected in supine position following 5 minutes of rest. Assessments were carried out at Weeks 4, 8, 12, 20, 28, 36, 44, 52 and Week 56. Baseline was defined as value at Week 0. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at the time of assessment.
Query!
Timepoint [10]
0
0
Baseline (Week 0) and Weeks 4, 8, 12, 20, 28, 36, 44, 52, 56
Query!
Secondary outcome [11]
0
0
Change From Baseline in Vital Sign Heart Rate Upto Week 56
Query!
Assessment method [11]
0
0
Vital sign assessment included heart rate collected in supine position following 5 minutes of rest. Assessments were carried out at Weeks 4, 8, 12, 20, 28, 36, 44, 52 and 56. Baseline was defined as value at Week 0. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at the time of assessment.
Query!
Timepoint [11]
0
0
Baseline (Week 0) and Weeks 4, 8, 12, 20, 28, 36, 44, 52 and 56
Query!
Secondary outcome [12]
0
0
Number of Participants With Shift From Baseline in Hematology Parameters
Query!
Assessment method [12]
0
0
Hematology parameters included platelets, neutrophils, lymphocytes, monocytes, eosinophils, basophils, hematocrit, red blood cell count, hemoglobin, white blood cell count and segmented neutrophils . Assessments were carried out at Weeks 4, 8, 12, 20, 28, 36, 44 and 52 and 56. The consolidated data for number of participants with shift from Baseline (change from Baseline) in hematology parameters characterized as high and low have been presented.
Query!
Timepoint [12]
0
0
Upto Week 56
Query!
Secondary outcome [13]
0
0
Number of Participants With Shift From Baseline in Clinical Chemistry Parameters
Query!
Assessment method [13]
0
0
Clinical chemistry parameters included total protein, phosphorous, albumin, sodium, potassium, chloride, calcium, glucose, gamma glutamyl transferase, total bilirubin, direct bilirubin, alkaline phosphatase, alanine amino transferase, aspartate amino transferase, blood urea nitrogen (BUN)/Urea, creatinine, uric acid, lactate dehydrogenase, bicarbonate, cholesterol and creatinine kinase. Assessments were carried out at Weeks 4, 8, 12, 20, 28, 36, 44, 52 and 56. The consolidated data for number of participants with shift from Baseline (change from Baseline) in clinical chemistry parameters characterized as high and low have been presented.
Query!
Timepoint [13]
0
0
Upto Week 56
Query!
Secondary outcome [14]
0
0
Change From Baseline in Liver Function Test Parameter Total Bilirubin at Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 and 56.
Query!
Assessment method [14]
0
0
Liver function test parameter included total bilirubin. Assessments were carried out at Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 and 56. Baseline was defined as value at Week 0. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at the time of assessment.
Query!
Timepoint [14]
0
0
Baseline (Week 0) and Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 and 56.
Query!
Secondary outcome [15]
0
0
Change From Baseline in Liver Function Test Parameter Albumin at Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and 56
Query!
Assessment method [15]
0
0
Liver function test parameter included albumin. Assessments were carried out at Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and 56.Baseline was defined as value at Week 0. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at the time of assessment.
Query!
Timepoint [15]
0
0
Baseline (Week 0) and Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and 56
Query!
Secondary outcome [16]
0
0
Change From Baseline in Liver Function Test Parameter Alanine Amino Transferase, Aspartate Amino Transferase, Alkaline Phosphatase and Gamma Glutamyl Transferase at Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and 56
Query!
Assessment method [16]
0
0
Liver function test parameters included alanine amino transferase, aspartate amino transferase, alkaline phosphatase and gamma glutamyl transferase. Assessments were carried out at Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and 56. Baseline was defined as value at Week 0. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at the time of assessment.
Query!
Timepoint [16]
0
0
Baseline (Week 0) and Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and 56
Query!
Secondary outcome [17]
0
0
Number of Participants With 12 Lead Electocardiogram (ECG) Abnormalities at Week 28 and 52
Query!
Assessment method [17]
0
0
A 12 lead ECG was collected at Weeks 28 and 52. ECG abnormalities were characterized as abnormal-not clinically significant (A-NCS) and abnormal-clinically significant (A-CS). A-NCS data for Week 28 and 52 have been presented.
Query!
Timepoint [17]
0
0
Week 28 and 52
Query!
Secondary outcome [18]
0
0
Change From Baseline in Short Form - 36 Version 2 (SF-36 v2) at Weeks 28 and 52
Query!
Assessment method [18]
0
0
The SF-36v2 health survey is a self-administered, generic, 36-item questionnaire designed to measure 8 domains of functional health status and well-being: physical functioning, role-physical, bodily pain, general health perceptions, vitality, social functioning, role-emotional, and mental health. Each domain is scored from 0 (poorer health) to 100 (better health). SF-36 v2 items are scored such that a higher score indicates a better health state and better functioning. Data for change from Baseline in SF-36 v2 at Weeks 28 and 52 was not collected following early termination of this study. Baseline was defined as value at Week 0. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at the time of assessment.
Query!
Timepoint [18]
0
0
Baseline (Week 0) and Weeks 28 and 52
Query!
Secondary outcome [19]
0
0
Change From Baseline in European Quality of Life (EuroQol ) Five Dimensions Questionnaire (EQ-5D) at Weeks 28 and 52
Query!
Assessment method [19]
0
0
EQ-5D self-reported questionnaire is used to measure health-related quality of life by measuring 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D questionnaire includes a visual analog scale (VAS) which records participants self-rated health status on a graduated (0-100) scale with higher scores indicating higher Health-Related Quality of Life (HRQoL). Data for Change from Baseline in EuroQol five dimensions questionnaire (EQ-5D) at Weeks 28 and 52 was not collected following early termination of this study. Baseline was defined as value at Week 0. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at the time of assessment.
Query!
Timepoint [19]
0
0
Baseline (Week 0) and Weeks 28 and 52
Query!
Secondary outcome [20]
0
0
Change From Baseline in Work Productivity & Activity Impairment - Crohn's Disease (WPAI-CD) at Weeks 28 and 52
Query!
Assessment method [20]
0
0
WPAI measures the effect of your CD on your ability to work and perform regular activities. 6-items assess impairment in work productivity and daily activity during the 7 days before the assessment. It measures the percentage of overall impairment in work productivity and daily activity due to CD. A WPAI score of 0% = no impairment and a score of 100% = total loss of work productivity or activity. An absolute change in WPAI score of 7% is considered the minimum clinically important difference (MCID). Data for change from Baseline in WPAI-CD at Weeks 28 and 52 was not collected following early termination of this study. Baseline was defined as value at Week 0. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at the time of assessment.
Query!
Timepoint [20]
0
0
Baseline (Week 0) and Weeks 28 and 52
Query!
Secondary outcome [21]
0
0
Receipt of Disability Benefits at Weeks 28 and 52
Query!
Assessment method [21]
0
0
Receipt of disability benefits (Yes/No) was to be recorded at Weeks 0, 28 and 52 and Early Withdrawal visit if applicable. Change from baseline in receipt of disability benefits was to be compared between participants in remission versus participants not in remission using a Wilcoxon rank sum test. Data for Receipt of disability benefits at Weeks 28 and 52 was not collected following early termination of this study.
Query!
Timepoint [21]
0
0
Weeks 28 and 52
Query!
Secondary outcome [22]
0
0
Change From Baseline in Health-related Resource Utilization at Weeks 28 and 52
Query!
Assessment method [22]
0
0
Healthcare related resource utilization was to include: Hospitalizations (all cause and Crohn's disease related), Length of stay, Surgical procedures (all cause and Crohn's disease related), Outpatient visits (all cause and Crohn's disease related ). The frequency of hospitalizations, surgical procedures and hospital out-patient visits were to be recorded at Weeks 28 and 52. The number and percentage of participants reporting all cause and Crohn's disease -related hospitalizations, surgeries, and hospital out-patient visits were to be summarized and compared between each GSK1605786A dose group and placebo using Fisher's exact test. Data for Change from Baseline in health-related resource utilization at Weeks 28 and 52 was not collected following early termination of this study. Baseline was defined as value at Week 0. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at the time of assessment.
Query!
Timepoint [22]
0
0
Baseline (Week 0) and Weeks 28 and 52
Query!
Secondary outcome [23]
0
0
Change From Baseline in C Reactive Protein (CRP) at Weeks 28 and 52
Query!
Assessment method [23]
0
0
C-reactive protein (CRP) at was to be assessed at Weeks 4, 8, 12, 20, 28, 36, 44, 52 visit if applicable. Data for Change from Baseline in C reactive protein (CRP) at Weeks 28 and 52 was not collected following early termination of this study. Baseline was defined as value at Week 0. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at the time of assessment.
Query!
Timepoint [23]
0
0
Baseline (Week 0 and Weeks 28 and 52
Query!
Secondary outcome [24]
0
0
Change From Baseline in Faecal Calprotectin at Weeks 28 and 52
Query!
Assessment method [24]
0
0
Stool sample for faecal calprotectin were to be collected at Weeks 28 and 52 visit if applicable. Data for Change from baseline in faecal calprotectin at Weeks 28 and 52 was not collected following early termination of this study. Baseline was defined as value at Week 0. Change from Baseline was calculated by subtracting the Baseline value from the post-randomization value at the time of assessment.
Query!
Timepoint [24]
0
0
Baseline (Week 0) and Weeks 28 and 52
Query!
Eligibility
Key inclusion criteria
- Subjects achieving clinical response (CDAI decrease of at least 100 points) and/or
remission (CDAI less than 150) upon completion of treatment in Study CCX114151 or
another GSK sponsored induction study
- Written informed consent prior to any CCX114157 specific study procedures
- Females of child-bearing potential must be sexually inactive or commit to use of
consistent and correct use of contraceptive methods with a failure rate of less than 1
percent
- Stable doses of Crohn's disease medications
- Subjects on corticosteroids at entry must be willing to undergo corticosteroid dose
taper during the study
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- If female, is pregnant, has a positive pregnancy test or is breast-feeding
- Subjects with known or suspected coeliac disease or a positive screening test
(anti-tissue transglutaminase antibodies) should have been excluded from enrolment
into the induction studies. Subjects in whom a diagnosis of coeliac disease is
subsequently suspected should have this excluded with testing for anti-tissue
transglutaminase antibodies prior to enrolment into the maintenance study.
- Known or suspected fixed symptomatic small bowel stricture
- Enterocutaneous, abdominal or pelvic fistulae likely to require surgery during the
study period
- Current sepsis or infections requiring intravenous antibiotic therapy for greater than
2 weeks
- Evidence of hepatic dysfunction, viral hepatitis, or liver function abnormalities
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
9/05/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
23/10/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
229
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - Bankstown
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Hersten
Query!
Recruitment hospital [3]
0
0
GSK Investigational Site - Adelaide
Query!
Recruitment hospital [4]
0
0
GSK Investigational Site - Kurralta Park
Query!
Recruitment hospital [5]
0
0
GSK Investigational Site - Box Hill
Query!
Recruitment hospital [6]
0
0
GSK Investigational Site - Fitzroy
Query!
Recruitment hospital [7]
0
0
GSK Investigational Site - Prahran
Query!
Recruitment hospital [8]
0
0
GSK Investigational Site - Fremantle
Query!
Recruitment postcode(s) [1]
0
0
2200 - Bankstown
Query!
Recruitment postcode(s) [2]
0
0
4029 - Hersten
Query!
Recruitment postcode(s) [3]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [4]
0
0
5037 - Kurralta Park
Query!
Recruitment postcode(s) [5]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [6]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [7]
0
0
3181 - Prahran
Query!
Recruitment postcode(s) [8]
0
0
6160 - Fremantle
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
District of Columbia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Indiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Kentucky
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Louisiana
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Maryland
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Massachusetts
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Michigan
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Minnesota
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Missouri
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New York
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
North Carolina
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Ohio
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Oklahoma
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Oregon
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Pennsylvania
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Tennessee
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Utah
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Virginia
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Washington
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Wisconsin
Query!
Country [28]
0
0
Austria
Query!
State/province [28]
0
0
Hall in Tirol
Query!
Country [29]
0
0
Austria
Query!
State/province [29]
0
0
Linz
Query!
Country [30]
0
0
Austria
Query!
State/province [30]
0
0
Oberpullendorf
Query!
Country [31]
0
0
Austria
Query!
State/province [31]
0
0
St.Veit/Glan
Query!
Country [32]
0
0
Austria
Query!
State/province [32]
0
0
Wien
Query!
Country [33]
0
0
Belgium
Query!
State/province [33]
0
0
Bonheiden
Query!
Country [34]
0
0
Belgium
Query!
State/province [34]
0
0
Brussels
Query!
Country [35]
0
0
Belgium
Query!
State/province [35]
0
0
Gent
Query!
Country [36]
0
0
Belgium
Query!
State/province [36]
0
0
Kortrijk
Query!
Country [37]
0
0
Belgium
Query!
State/province [37]
0
0
Leuven
Query!
Country [38]
0
0
Belgium
Query!
State/province [38]
0
0
Roeselare
Query!
Country [39]
0
0
Bulgaria
Query!
State/province [39]
0
0
Plovdiv
Query!
Country [40]
0
0
Bulgaria
Query!
State/province [40]
0
0
Sofia
Query!
Country [41]
0
0
Bulgaria
Query!
State/province [41]
0
0
Varna
Query!
Country [42]
0
0
Canada
Query!
State/province [42]
0
0
Alberta
Query!
Country [43]
0
0
Canada
Query!
State/province [43]
0
0
British Columbia
Query!
Country [44]
0
0
Canada
Query!
State/province [44]
0
0
Manitoba
Query!
Country [45]
0
0
Canada
Query!
State/province [45]
0
0
Nova Scotia
Query!
Country [46]
0
0
Canada
Query!
State/province [46]
0
0
Ontario
Query!
Country [47]
0
0
Canada
Query!
State/province [47]
0
0
Quebec
Query!
Country [48]
0
0
Chile
Query!
State/province [48]
0
0
Vina del Mar
Query!
Country [49]
0
0
Czechia
Query!
State/province [49]
0
0
Hradec Králové
Query!
Country [50]
0
0
Czechia
Query!
State/province [50]
0
0
Olomouc
Query!
Country [51]
0
0
Czechia
Query!
State/province [51]
0
0
Ostrava - Vitkovice
Query!
Country [52]
0
0
Czechia
Query!
State/province [52]
0
0
Praha 10
Query!
Country [53]
0
0
Czechia
Query!
State/province [53]
0
0
Praha 4
Query!
Country [54]
0
0
Czechia
Query!
State/province [54]
0
0
Praha 7
Query!
Country [55]
0
0
Czechia
Query!
State/province [55]
0
0
Praha 9
Query!
Country [56]
0
0
Denmark
Query!
State/province [56]
0
0
Aalborg
Query!
Country [57]
0
0
Denmark
Query!
State/province [57]
0
0
Aarhus
Query!
Country [58]
0
0
Denmark
Query!
State/province [58]
0
0
Herlev
Query!
Country [59]
0
0
Denmark
Query!
State/province [59]
0
0
Hvidovre
Query!
Country [60]
0
0
Denmark
Query!
State/province [60]
0
0
Odense
Query!
Country [61]
0
0
Estonia
Query!
State/province [61]
0
0
Tallinn
Query!
Country [62]
0
0
Estonia
Query!
State/province [62]
0
0
Tartu
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
Clichy cedex
Query!
Country [64]
0
0
France
Query!
State/province [64]
0
0
Lille cedex
Query!
Country [65]
0
0
France
Query!
State/province [65]
0
0
Nantes cedex 1
Query!
Country [66]
0
0
France
Query!
State/province [66]
0
0
Nice cedex 3
Query!
Country [67]
0
0
France
Query!
State/province [67]
0
0
Paris cedex 10
Query!
Country [68]
0
0
France
Query!
State/province [68]
0
0
Pessac cedex
Query!
Country [69]
0
0
France
Query!
State/province [69]
0
0
Saint-Priest en Jarez
Query!
Country [70]
0
0
France
Query!
State/province [70]
0
0
Vandoeuvre Les Nancy
Query!
Country [71]
0
0
Germany
Query!
State/province [71]
0
0
Baden-Wuerttemberg
Query!
Country [72]
0
0
Germany
Query!
State/province [72]
0
0
Hessen
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Niedersachsen
Query!
Country [74]
0
0
Germany
Query!
State/province [74]
0
0
Nordrhein-Westfalen
Query!
Country [75]
0
0
Germany
Query!
State/province [75]
0
0
Berlin
Query!
Country [76]
0
0
Germany
Query!
State/province [76]
0
0
Hamburg
Query!
Country [77]
0
0
Hong Kong
Query!
State/province [77]
0
0
Hong Kong
Query!
Country [78]
0
0
Hong Kong
Query!
State/province [78]
0
0
Shatin, New Territories
Query!
Country [79]
0
0
Hungary
Query!
State/province [79]
0
0
Bekescsaba
Query!
Country [80]
0
0
Hungary
Query!
State/province [80]
0
0
Budapest
Query!
Country [81]
0
0
Hungary
Query!
State/province [81]
0
0
Debrecen
Query!
Country [82]
0
0
Hungary
Query!
State/province [82]
0
0
Mosonmagyaróvár
Query!
Country [83]
0
0
Hungary
Query!
State/province [83]
0
0
Szekszárd
Query!
Country [84]
0
0
Hungary
Query!
State/province [84]
0
0
Vác
Query!
Country [85]
0
0
Israel
Query!
State/province [85]
0
0
Afula
Query!
Country [86]
0
0
Israel
Query!
State/province [86]
0
0
Beer Sheva
Query!
Country [87]
0
0
Israel
Query!
State/province [87]
0
0
Haifa
Query!
Country [88]
0
0
Israel
Query!
State/province [88]
0
0
Holon
Query!
Country [89]
0
0
Israel
Query!
State/province [89]
0
0
Jerusalem
Query!
Country [90]
0
0
Israel
Query!
State/province [90]
0
0
Kfar Saba
Query!
Country [91]
0
0
Israel
Query!
State/province [91]
0
0
Petah Tikva
Query!
Country [92]
0
0
Israel
Query!
State/province [92]
0
0
Ramat-Gan
Query!
Country [93]
0
0
Israel
Query!
State/province [93]
0
0
Tel Aviv
Query!
Country [94]
0
0
Israel
Query!
State/province [94]
0
0
Zerifin
Query!
Country [95]
0
0
Italy
Query!
State/province [95]
0
0
Sicilia
Query!
Country [96]
0
0
Italy
Query!
State/province [96]
0
0
Genova
Query!
Country [97]
0
0
Italy
Query!
State/province [97]
0
0
Modena
Query!
Country [98]
0
0
Italy
Query!
State/province [98]
0
0
Roma
Query!
Country [99]
0
0
Japan
Query!
State/province [99]
0
0
Aichi
Query!
Country [100]
0
0
Japan
Query!
State/province [100]
0
0
Chiba
Query!
Country [101]
0
0
Japan
Query!
State/province [101]
0
0
Fukuoka
Query!
Country [102]
0
0
Japan
Query!
State/province [102]
0
0
Hiroshima
Query!
Country [103]
0
0
Japan
Query!
State/province [103]
0
0
Hokkaido
Query!
Country [104]
0
0
Japan
Query!
State/province [104]
0
0
Hyogo
Query!
Country [105]
0
0
Japan
Query!
State/province [105]
0
0
Kagoshima
Query!
Country [106]
0
0
Japan
Query!
State/province [106]
0
0
Miyagi
Query!
Country [107]
0
0
Japan
Query!
State/province [107]
0
0
Osaka
Query!
Country [108]
0
0
Japan
Query!
State/province [108]
0
0
Tokyo
Query!
Country [109]
0
0
Korea, Republic of
Query!
State/province [109]
0
0
Daegu
Query!
Country [110]
0
0
Korea, Republic of
Query!
State/province [110]
0
0
Pusan
Query!
Country [111]
0
0
Korea, Republic of
Query!
State/province [111]
0
0
Seoul
Query!
Country [112]
0
0
Korea, Republic of
Query!
State/province [112]
0
0
Wonju
Query!
Country [113]
0
0
Netherlands
Query!
State/province [113]
0
0
Amsterdam
Query!
Country [114]
0
0
Netherlands
Query!
State/province [114]
0
0
EDE
Query!
Country [115]
0
0
Netherlands
Query!
State/province [115]
0
0
Eindhoven
Query!
Country [116]
0
0
Netherlands
Query!
State/province [116]
0
0
Rotterdam
Query!
Country [117]
0
0
New Zealand
Query!
State/province [117]
0
0
Dunedin
Query!
Country [118]
0
0
New Zealand
Query!
State/province [118]
0
0
Lower Hutt
Query!
Country [119]
0
0
New Zealand
Query!
State/province [119]
0
0
Otahuhu, Auckland
Query!
Country [120]
0
0
New Zealand
Query!
State/province [120]
0
0
Tauranga.
Query!
Country [121]
0
0
Norway
Query!
State/province [121]
0
0
Tromsø
Query!
Country [122]
0
0
Norway
Query!
State/province [122]
0
0
Tønsberg
Query!
Country [123]
0
0
Poland
Query!
State/province [123]
0
0
Bydgoszcz
Query!
Country [124]
0
0
Poland
Query!
State/province [124]
0
0
Lublin
Query!
Country [125]
0
0
Poland
Query!
State/province [125]
0
0
Sopot
Query!
Country [126]
0
0
Poland
Query!
State/province [126]
0
0
Torun
Query!
Country [127]
0
0
Poland
Query!
State/province [127]
0
0
Wroclaw
Query!
Country [128]
0
0
Portugal
Query!
State/province [128]
0
0
Lisboa
Query!
Country [129]
0
0
Portugal
Query!
State/province [129]
0
0
Porto
Query!
Country [130]
0
0
Portugal
Query!
State/province [130]
0
0
Viseu
Query!
Country [131]
0
0
Russian Federation
Query!
State/province [131]
0
0
Irkutsk
Query!
Country [132]
0
0
Russian Federation
Query!
State/province [132]
0
0
Kazan
Query!
Country [133]
0
0
Russian Federation
Query!
State/province [133]
0
0
Lipetsk
Query!
Country [134]
0
0
Russian Federation
Query!
State/province [134]
0
0
Moscow
Query!
Country [135]
0
0
Russian Federation
Query!
State/province [135]
0
0
Nizhniy Novgorod
Query!
Country [136]
0
0
Russian Federation
Query!
State/province [136]
0
0
Rostov-on-Don
Query!
Country [137]
0
0
Russian Federation
Query!
State/province [137]
0
0
Samara
Query!
Country [138]
0
0
Russian Federation
Query!
State/province [138]
0
0
St. Petersburg
Query!
Country [139]
0
0
Russian Federation
Query!
State/province [139]
0
0
Tomsk
Query!
Country [140]
0
0
Slovakia
Query!
State/province [140]
0
0
Bratislava
Query!
Country [141]
0
0
Slovakia
Query!
State/province [141]
0
0
Nitra
Query!
Country [142]
0
0
Slovakia
Query!
State/province [142]
0
0
Nove Mesto nad Vahom
Query!
Country [143]
0
0
Slovakia
Query!
State/province [143]
0
0
Presov
Query!
Country [144]
0
0
Slovakia
Query!
State/province [144]
0
0
Trnava
Query!
Country [145]
0
0
South Africa
Query!
State/province [145]
0
0
Bellville
Query!
Country [146]
0
0
South Africa
Query!
State/province [146]
0
0
Claremont
Query!
Country [147]
0
0
South Africa
Query!
State/province [147]
0
0
Observatory
Query!
Country [148]
0
0
South Africa
Query!
State/province [148]
0
0
Parktown
Query!
Country [149]
0
0
Spain
Query!
State/province [149]
0
0
Badalona
Query!
Country [150]
0
0
Spain
Query!
State/province [150]
0
0
Elche
Query!
Country [151]
0
0
Spain
Query!
State/province [151]
0
0
Fuenlabrada (Madrid)
Query!
Country [152]
0
0
Spain
Query!
State/province [152]
0
0
Galdakao/Vizcaya
Query!
Country [153]
0
0
Spain
Query!
State/province [153]
0
0
Madrid
Query!
Country [154]
0
0
Spain
Query!
State/province [154]
0
0
Marbella
Query!
Country [155]
0
0
Spain
Query!
State/province [155]
0
0
Sabadell (Barcelona)
Query!
Country [156]
0
0
Spain
Query!
State/province [156]
0
0
Santander (Cantabria)
Query!
Country [157]
0
0
Sweden
Query!
State/province [157]
0
0
Lund
Query!
Country [158]
0
0
Sweden
Query!
State/province [158]
0
0
Stockholm
Query!
Country [159]
0
0
Switzerland
Query!
State/province [159]
0
0
Bern
Query!
Country [160]
0
0
Switzerland
Query!
State/province [160]
0
0
Zürich
Query!
Country [161]
0
0
Taiwan
Query!
State/province [161]
0
0
Taichung
Query!
Country [162]
0
0
Turkey
Query!
State/province [162]
0
0
Ankara
Query!
Country [163]
0
0
Ukraine
Query!
State/province [163]
0
0
Chernivtsi
Query!
Country [164]
0
0
Ukraine
Query!
State/province [164]
0
0
Dnipropetrovsk
Query!
Country [165]
0
0
Ukraine
Query!
State/province [165]
0
0
Donetsk
Query!
Country [166]
0
0
Ukraine
Query!
State/province [166]
0
0
Kharkiv
Query!
Country [167]
0
0
Ukraine
Query!
State/province [167]
0
0
Kyiv
Query!
Country [168]
0
0
Ukraine
Query!
State/province [168]
0
0
Odesa
Query!
Country [169]
0
0
Ukraine
Query!
State/province [169]
0
0
Simferopol
Query!
Country [170]
0
0
Ukraine
Query!
State/province [170]
0
0
Vinnytsya
Query!
Country [171]
0
0
United Kingdom
Query!
State/province [171]
0
0
Middlesex
Query!
Country [172]
0
0
United Kingdom
Query!
State/province [172]
0
0
Birmingham
Query!
Country [173]
0
0
United Kingdom
Query!
State/province [173]
0
0
Bristol
Query!
Country [174]
0
0
United Kingdom
Query!
State/province [174]
0
0
Edinburgh
Query!
Country [175]
0
0
United Kingdom
Query!
State/province [175]
0
0
Manchester
Query!
Country [176]
0
0
United Kingdom
Query!
State/province [176]
0
0
Newcastle-upon-Tyne
Query!
Country [177]
0
0
United Kingdom
Query!
State/province [177]
0
0
Oxford
Query!
Country [178]
0
0
United Kingdom
Query!
State/province [178]
0
0
Salford
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of
two doses (500 mg once daily and 500 mg twice daily) of GSK1605786A in maintaining remission
over 52 weeks in adult subjects with Crohn's disease. Efficacy will be assessed by the
Crohn's Disease Activity Index (CDAI) score. Eligible subjects will have achieved response
(CDAI decrease of at least 100 points) and/or remission (CDAI less than 150) in a prior GSK
sponsored induction study. The primary endpoint will be proportion of subjects in remission
at both Weeks 28 and 52. Safety will be assessed by recording of adverse events, clinical
laboratory parameters including liver function tests, vital signs and electrocardiogram.
Population pharmacokinetics will evaluate the two doses of GSK1605786A. Health outcomes
assessments will include changes in Inflammatory Bowel Disease Questionnaire (IBDQ), SF-36v2,
EQ-5D, Work Productivity and Activity Impairment - Crohn's Disease (WPAI-CD) and disability.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01316939
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01316939
Download to PDF